MedPath

ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc. logo
🇺🇸United States
Ownership
Public
Established
2021-01-01
Employees
40
Market Cap
$931M
Website
http://www.arrivent.com

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Phase 3
Active, not recruiting
Conditions
Metastatic Non-Small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer
EGFR Exon 20 Mutations
Interventions
First Posted Date
2022-11-07
Last Posted Date
2025-04-22
Lead Sponsor
ArriVent BioPharma, Inc.
Target Recruit Count
398
Registration Number
NCT05607550
Locations
🇬🇧

Arrivent Investigative Site, Bebington, Wirral, United Kingdom

🇺🇸

Arrivent Investigative site, Sacramento, California, United States

🇬🇧

ArriVent Investigative Site, Sutton, United Kingdom

and more 1 locations

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Phase 1
Active, not recruiting
Conditions
EGFR Exon 20 Mutations
HER2 Exon 20 Mutations
Metastatic Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer (NSCLC)
Advanced Non-Small Cell Lung Cancer
EGFR Uncommon Mutations, Including G719X and S768I
Interventions
First Posted Date
2022-05-06
Last Posted Date
2025-05-01
Lead Sponsor
ArriVent BioPharma, Inc.
Target Recruit Count
170
Registration Number
NCT05364073
Locations
🇬🇧

ArriVent Investigative Site, London, United Kingdom

🇳🇱

Arrivent Investigative Site, Amsterdam, Noord-Holland, Netherlands

🇨🇳

Allist Investigative Site, Taiyuan, Shanxi, China

© Copyright 2025. All Rights Reserved by MedPath